Financial Reports Latest Updates Industry Maps Economic Calendar

AEON Biopharma, Inc. (AEON) Annual Reports

Q: Where can I read AEON Biopharma, Inc. (AEON) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

AEON Biopharma, Inc. is listed on NYSE, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： NYSE
Fiscal year end： 12/31
SEC CIK： 1837607 →

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Operating income	$-5.9M	$-4.3M	-36.4%
Net income	$-1.2M	$-6.6M	+82.6%
EPS (diluted)	$-0.02	$-0.60	+96.7%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Net income -1.15 mn

Show table：Income statement

Item	2021Q1	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating income	0	0.2	-0.4	-0.45	-0.89	-0.39	-0.43	-0.49	-2.02	-1.74	-3.53	-2.63	64.3	-28.3	-74.2	153	-4.02	-2.32	-0.46	-4.34	-2.49	-5.51	-5.93	-5.92
Net income	0	6.32	-4.03	5.66	0.25	2.77	1.87	1.64	3.70	-0.39	-3.94	-5.00	43.9	-19.8	-118	164	-6.17	2.08	9.10	-6.64	-4.54	-37.1	-11.8	-1.15

Balance sheet

Quarterly · In mn (USD)

Total assets 5.91 mn Total liabilities 21.3 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2021Q1	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	0.08	2.14	1.38	1.03	0.84	0.52	0.25	0.17	0.11	0.54	0.59	—	16.9	6.22	2.50	4.02	2.37	1.59	12.3	10.3	7.41	3.40	6.63	3.99
Total assets	0.08	278	278	277	277	277	277	277	279	21.6	21.8	—	17.6	6.85	3.03	5.73	4.00	3.14	13.8	11.7	8.73	5.56	8.63	5.91
Current liabilities	0.06	0.47	0.21	0.22	0.83	0.79	0.97	1.35	3.88	5.87	9.46	—	14.2	13.1	16.0	10.4	10.7	14.2	8.64	9.13	8.23	6.90	6.67	7.34
Total liabilities	0.06	21.0	24.4	22.2	17.9	14.8	12.8	12.0	10.4	7.94	12.1	—	139	160	201	33.7	36.1	31.7	25.1	27.5	28.6	60.6	25.4	21.3
Equity	0.02	5.00	5.00	-17.2	-16.9	-14.2	-12.4	-11.6	-9.44	-7.32	-11.5	-288	-122	-153	-198	-27.9	-32.1	-28.6	-11.3	-15.8	-19.9	-55.0	-16.8	-15.4

Cash flow

Quarterly · In mn (USD)

Operating -3.70 mn Investing 0 mn Financing 0.89 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2021Q1	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	—	0.55	-1.56	-0.33	-0.16	-0.41	-0.16	-0.24	-0.17	-0.62	-0.95	-20.2	-15.1	-11.0	-8.60	-8.12	-2.95	-0.62	-7.91	-2.09	-2.60	-4.71	-2.64	-3.70
Investing	—	276	-552	0	0	0.08	0	0.26	0.06	260	0.08	—	—	—	—	—	—	—	0	0	0	0	—	—
Financing	—	278	0	0	0	—	—	44.5	-44.4	-259	0.85	272	—	—	5.00	10.0	0.05	0.1	18.4	0.08	0.08	1.79	5.87	0.89
Cash at period end	0	1.44	0.99	0.66	0.5	0.17	0.01	0.03	9.75	0.46	0.44	31.2	16.2	5.16	1.56	3.44	0.54	0.01	10.4	8.44	5.93	3.01	6.24	3.43

Returns & leverage

Quarterly · %

ROA -621.7% Debt ratio 359.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2021Q1	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROA	—	—	—	2.9%	5.9%	1.7%	3.8%	2.4%	3.6%	4.6%	0.7%	—	23.3%	106.1%	-797.6%	1223.2%	185.9%	841.2%	2009.6%	-18.8%	-0.1%	-901.5%	-536.0%	-621.7%
Debt ratio	73.6%	7.5%	8.8%	8.0%	6.5%	5.3%	4.6%	4.3%	3.7%	36.7%	55.3%	—	791.0%	2335.8%	6642.9%	587.4%	901.5%	1009.3%	182.1%	235.9%	327.5%	1089.7%	294.1%	359.9%

EPS

Quarterly · US$

EPS US$-0.02

Show table：EPS

Item	2021Q1	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	-0.08	-0.25	-0.13	-0.11	-0.04	1.35	-0.54	-3.17	4.22	-0.16	71.96	2.28	-0.60	-0.39	-3.72	-0.29	-0.02

Revenue & profit

Year-to-date · In mn (USD)

Net income -12.9 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 5.91 mn Total liabilities 21.3 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -6.33 mn Investing 0 mn Financing 6.76 mn

Positive = cash in, negative = cash out.

Returns & leverage

Year-to-date · %

ROA -621.7% Debt ratio 359.9%

EPS

Year-to-date · US$

EPS US$-0.31

Revenue & profit

Annual · In mn (USD)

Net income -39.2 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2021	2022	2024	2025
Operating income	-1.54	-3.33	101	-12.8
Net income	8.20	9.98	56.7	-39.2

Balance sheet

Annual · In mn (USD)

Total assets 5.56 mn Total liabilities 60.6 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2021	2022	2024	2025
Current assets	0.84	0.11	1.59	3.40
Total assets	277	279	3.14	5.56
Current liabilities	0.83	3.88	14.2	6.90
Total liabilities	17.9	10.4	31.7	60.6
Equity	-16.9	-9.44	-28.6	-55.0

Cash flow

Annual · In mn (USD)

Operating -17.3 mn Investing 0 mn Financing 20.3 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2021	2022	2024	2025
Operating	—	-0.98	-68.1	-17.3
Investing	—	0.4	—	0
Financing	—	—	—	20.3
Cash at period end	0.5	9.75	0.01	3.01

Returns & leverage

Annual · %

ROA -901.5% Debt ratio 1089.7%

Show table：Returns & leverage

Item	2021	2022	2024	2025
ROA	3.0%	3.6%	40.1%	-901.5%
Debt ratio	6.5%	3.7%	1009.3%	1089.7%

EPS

Annual · US$

EPS US$-2.43

Show table：EPS

Item	2021	2022	2024	2025
EPS（US$）	—	—	73.38	-2.43

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read AEON Biopharma, Inc. (AEON) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.